33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): Final time to next therapy (TTNT) results from the phase 3 ALCANZA study
    Meeting Abstract

    Scarisbrick, J.; Horwitz, S. M.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Outcomes and prognostic factors in African American/Black patients with mycosis fungoides and Sézary syndrome
    Meeting Abstract

    Geller, S.; Lebowitz, E.; Pulitzer, M. P.; Horwitz, S. M.; Moskowitz, A. J.; Dusza, S.; Myskowski, P. L.
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: Results of the Consensus Histopathologic Review
    Meeting Abstract

    Gru, A. A.; Mitteldorf, C.; Pulitzer, M.; Hodak, E.; Scarisbrick, J.; Zic, J.; Kempf, W.; Guenova, E.; Haun, P.; Torres-Cabala, C.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: An international virtual study
    Meeting Abstract

    Hodak, E.; Zic, J.; Bagot, M.; Gru, A. A.; Battistella, M.; Mitteldorf, C.; Cozzio, A.; Guenova-Hötzenecker, E.; Guitart, J.; Geskin, L.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)
    Meeting Abstract

    Tawbi, H.; Forsyth, P.; Hodi, F. S.; Lao, C.; Moschos, S.; Hamid, O.; Atkins, M. B.; Lewis, K.; Thomas, R. P.; Glaspy, J. A.; more...
    British Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis
    Meeting Abstract

    Paz-Ares, L.; Ciuleanu, T. E.; Yu, X.; Salman, P.; Pluzanski, A.; Nagrial, A.; Havel, L.; Kowalyszyn, R.; Audigier-Valette, C.; Wu, Y. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Interim results from the IMPACT study: Evidence for PSA screening in BRCA2 mutation carriers
    Meeting Abstract

    Page, E.; Bancroft, E.; Brook, M.; Assel, M.; Offman, J.; Kote-Jarai, Z.; Vickers, A.; Lilja, H.; Eeles, R.
    British Journal of Cancer (2019)

    Fulltext@MSK | Save
  • BEACON: A randomised, phase 3 study of encorafenib and cetuximab +/- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients
    Meeting Abstract

    Wasan, H.; Arkenau, T.; Braun, M.; Samuel, L.; Graham, J.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Yoshino, T.; more...
    British Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
    Meeting Abstract

    Ziegler, D. S.; Doz, F.; Geoerger, B.; Dubois, S.; Grilley-Olson, J. E.; van Tilburg, C.; Italiano, A.; Lissat, A.; Kang, J. H.; Tahara, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
    Meeting Abstract

    Yamazaki, K.; Ryoo, B. Y.; Doi, T.; Paik, P. K.; Veillon, R.; Decaens, T.; Faivre, S.; Falchook, G. S.; Hong, D. S.; Scheele, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save